Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$55.10 USD
+2.55 (4.85%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $55.10 0.00 (0.00%) 7:48 PM ET
1-Strong Buy of 5 1
B Value B Growth B Momentum A VGM
Brokerage Reports
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 141 - 160 ( 195 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Results and Update - Lowering Fair Value to $6 from $13
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
No Backpedaling from ROCHE on sub cu HERCEPTIN during the US Analyst Presentation -- REITERATE NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL and Removing from Best Ideas List -- ROCHE Downplays subcutaneous HERCEPTIN
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Partnering Progress Validates Technology; Additional Deals Likely in Near-term, Potentially by Year-End 2012 - Reiterate OUTPERFORM and Best Idea
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BEST IDEAS LIST-Best Ideas List -- November 2012 Performance
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of November 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Raising FV to $17 - Analyst Day Takeaways: 2013 Hylenex Insulin Pump Upside and HTI-501 in Cellulite Partnering Opportunities
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ESMO Herceptin Data Supports Current Length of Treatment - Preserves Herceptin SC Opportunity - Reiterate OUTPERFORM and BEST IDEA
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 30.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Analyst Day Preview: UpsideOpportunities in Insulin Delivery
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
September 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 9, 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:12 Update - Buying Opportunity as rHuPH20 Concerns Overdone - Hylenex, Insulin and Roche Programs.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Believe Sell-off Overdone - Concerns ONLY Related to Plasma-Derived Product Combos
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
August 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
July 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ADA Data Confirms Hylenex Facilitates Tighter Glucose Control
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G